A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
Kyowa Kirin to Enhance Nephrology Lineup with DPP-4 Inhibitor; Companies Aiming to Capture Market through “2-Sword” Strategy
To read the full story
Related Article
- Sanofi K.K. Acquires DPP-4, SGLT-2 Inhibitors from Novartis, Chugai Aiming for Growth of Its Own Major Products for Diabetes through Synergism
January 7, 2013
- Lilly and BI in Long-term Collaboration; AZ and BMS Expanding Product Lineup
January 7, 2013
- Kowa Acquires 2 Major Products for “Post-Livalo” Era; How to Avoid Competition between Partners Holds Key in Comarketing
January 7, 2013
BUSINESS
- Chugai Sees 20% of Workforce Apply for Internal Job Postings
July 29, 2025
- Stella to Seek Japan Approval for BNCT as Angiosarcoma Trial Hits Goal
July 29, 2025
- Deciphera’s TGCT Drug Gets Key EMA Backing: Ono
July 29, 2025
- Opdivo-Yervoy Combo Approved for 1st Line HCC in Taiwan
July 29, 2025
- Shionogi, Torii to Start Co-Promotion in September upon Takeover
July 29, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…